Shares of Eli Lilly (LLY) and Novo Nordisk (NVO) were up on Tuesday, likely due to a proposal by President Biden that Medicare and Medicaid should cover the cost of obesity treatments. The new proposal, if passed, will significantly expand access for Lilly and Novo Nordisk’s currently marketed weekly injections to treat obesity, Zepbound and Wegovy, respectively. Zepbound is marketed as Mounjaro and Wegovy as Ozempic for type II diabetes. Both Mounjaro and Ozempic are also prescribed by doctors off-label fo ...